Breast cancer, metastatic
Invited discussant abstracts 222O and 223O
Date
08 Oct 2016Session
Breast cancer, metastaticPresenters
Javier Cortes CastanAuthors
J. Cortes CastanAuthor affiliations
- Oncology, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
2898 - FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer
Presenter: Matthew Ellis
Session: Breast cancer, metastatic
Resources:
Abstract
3504 - Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)
Presenter: Richard Finn
Session: Breast cancer, metastatic
Resources:
Abstract
Slides
3406 - BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC)
Presenter: Melanie Royce
Session: Breast cancer, metastatic
Resources:
Abstract
Slides
2333 - Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial
Presenter: Judith Balmaña
Session: Breast cancer, metastatic
Resources:
Abstract
Slides
1640 - Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab
Presenter: Hope Rugo
Session: Breast cancer, metastatic
Resources:
Abstract
4585 - Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation
Presenter: Kenji Tamura
Session: Breast cancer, metastatic
Resources:
Abstract
3854 - Efficacy and safety of BCD-022, trastuzumab biosimilar candidate, compared to herceptin: Results of international multicenter randomized double blind study in patients with HER2+ mBC
Presenter: Maria Shustova
Session: Breast cancer, metastatic
Resources:
Abstract
Invited discussant abstracts LBA16, LBA17 and 224PD
Presenter: Cristina Saura
Session: Breast cancer, metastatic
Resources:
Slides
Webcast
774 - A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer
Presenter: Muralidhar Beeram
Session: Breast cancer, metastatic
Resources:
Abstract
2627 - Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2
Presenter: Hope Rugo
Session: Breast cancer, metastatic
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.